| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00000478-200404000-00005 |
| P8608 | Fatcat ID | release_unjpklm6zbcytb5qpsrup3zddm |
| P698 | PubMed publication ID | 15087665 |
| P2093 | author name string | Sherrie L Perkins | |
| Chung-Che Chang | |||
| David H Vesole | |||
| Brent Logan | |||
| Andre Kajdacsy-Balla | |||
| Sara McClintock | |||
| Ronald P Cleveland | |||
| Trent Trzpuc | |||
| P2860 | cites work | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunohistochemistry | Q899285 |
| P304 | page(s) | 464-470 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | The American Journal of Surgical Pathology | Q7713508 |
| P1476 | title | Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma | |
| P478 | volume | 28 |
| Q37037156 | A Study of the Newer Prognostic Markers in Diffuse Large B Cell Lymphomas |
| Q37186576 | A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus |
| Q36171783 | A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study |
| Q28256358 | A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy |
| Q46884974 | A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin |
| Q53638690 | AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles |
| Q51911790 | Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. |
| Q24556523 | Accumulation of miR-155 and BIC RNA in human B cell lymphomas |
| Q36965870 | B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice |
| Q81592213 | Bcl-6 predicts improved prognosis in primary central nervous system lymphoma |
| Q45128237 | Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience. |
| Q35713686 | Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era |
| Q51276077 | Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment |
| Q53256322 | Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma |
| Q47246325 | Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier. |
| Q33801163 | Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17 |
| Q42104119 | Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study |
| Q28731283 | Development of Multigene Expression Signature Maps at the Protein Level from Digitized Immunohistochemistry Slides |
| Q38882112 | Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine |
| Q41872455 | Diffuse large B-cell lymphoma, not otherwise specified of the palate: A case report |
| Q36622610 | Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities |
| Q92664237 | Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL |
| Q37763784 | Epigenetic therapy of lymphoma using histone deacetylase inhibitors |
| Q85003497 | Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis |
| Q28253182 | Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis |
| Q36865089 | Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma |
| Q81791444 | Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma |
| Q38321470 | Expression of Toll‐like receptor9 in diffuse large B‐cell lymphoma: further exploring CpG oligodeoxynucleotide in NFκB pathway |
| Q53325724 | Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases |
| Q34753447 | Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma |
| Q33560762 | Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France |
| Q34585452 | HIV infection and lymphoma |
| Q83820573 | High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia |
| Q46409867 | Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls |
| Q33518060 | Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda |
| Q34096570 | Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas |
| Q45372503 | Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection |
| Q44813152 | Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases |
| Q82485637 | Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy |
| Q33561185 | Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034 |
| Q35932225 | Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry |
| Q37831960 | Impact of gene expression profiling in lymphoma diagnosis and prognosis. |
| Q51218335 | Large Cell Lymphoma: Correlation of HIV Status and Prognosis with Differentiation Profiles Assessed by Immunophenotyping |
| Q37406798 | Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials |
| Q84767205 | Molecular pathogenesis of diffuse large B-cell lymphoma |
| Q38065892 | Molecular pathology of lymphoma |
| Q57615261 | Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases |
| Q58777082 | Mutations in isocitrate dehydrogenase isoforms 1 and 2 are rare events in primary central nervous system and non-central nervous system diffuse large B cell lymphoma |
| Q37457207 | Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome |
| Q37265785 | Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group |
| Q41076269 | Pediatric non-Hodgkin lymphomas: first report from Central Africa |
| Q44972706 | Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles |
| Q54592303 | Polyostotic primary bone lymphoma with progression limited in the skeleton: Identical clonal origin of the initial and progressed tumors and a late relapse by VDJ rearrangement analysis. |
| Q38872027 | Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulation |
| Q37145006 | Primary Pancreatic Lymphoma Presenting as Acute Pancreatitis |
| Q34574781 | Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: Immunophenotypic subtypes and Epstein-Barr virus association |
| Q37269004 | Primary mediastinal B-cell lymphoma: detection of BCL2 gene rearrangements by PCR analysis and FISH |
| Q51901667 | Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups |
| Q37280910 | Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas |
| Q51720793 | Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study |
| Q37313308 | Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor |
| Q37635115 | Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. |
| Q42642003 | Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma |
| Q37269036 | Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. |
| Q45124110 | Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma |
| Q82270556 | Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT |
| Q58567593 | Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP |
| Q36971217 | Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3 |
| Q28256567 | Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab |
| Q51759886 | Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma |
| Q92617944 | Prognostic significance of immunohistochemical subtypes based on the stage of B-cell differentiation in primary CNS lymphoma |
| Q46157979 | Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP. |
| Q35590607 | Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy. |
| Q48378085 | Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma |
| Q42807725 | Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. |
| Q28294060 | RETRACTED: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) |
| Q35006744 | Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas |
| Q36752014 | Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma |
| Q53220165 | Spontaneous Remission in Localized Diffuse Large B-cell Lymphoma |
| Q37109671 | Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. |
| Q39221506 | The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects |
| Q34313320 | The biology of human lymphoid malignancies revealed by gene expression profiling. |
| Q46796219 | The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma |
| Q36559885 | The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma |
| Q37174123 | The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. |
| Q51582866 | The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas |
| Q40649778 | The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. |
| Q38888975 | The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma |
| Q39367516 | Tissue microarray in a subset of South African patients with DLBCL. |
| Q39965971 | Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. |
| Q36194645 | Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma |
| Q35235728 | p52 Activation in Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder/Diffuse Large B-Cell Lymphoma without BAFF-R Expression |
Search more.